CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

Home > Press room > CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

November 5, 2020

A collaboration between Perceiv AI, DalCor Pharmaceuticals and the Montreal Heart Institute

The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

the project supports the development of AI-driven digital biomarkers to identify patients who would specifically benefit from given medicines being tested in cardiovascular disease clinical trials.

find out more by visiting the Institute’s website

Get all the latest news!

By signing up for our newsletter, you’ll be getting the latest news about the Foundation delivered directly to your inbox.

This field is required
This field is required
This field is requiredAdresse courriel invalide

This field is required
Please leave this
field empty